Safety and Dose-escalation Study of AAV2-hCHM in Participants With CHM (Choroideremia) Gene Mutations

NCT02341807 · clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
COMPLETED
Status
15
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Spark Therapeutics, Inc.